Financial Stability Considerations for Newly Separated Parents Rent vs Buy Meta to Launch AI Subscription Plans Starting at 799 Per Month in Initial Test Phase Torrent Pharma Reports 26 Drop in Q4 Profit Amid JB Pharma Acquisition Costs and Severance Board Approves 5000 Crore QIP Viking Therapeutics Acquisition Scenario Which Stakeholders Could Benefit GLOBALFOUNDRIES Inc Launches Quantum Technology Solutions A New Frontier in Semiconductor Manufacturing SP Upgrades Lockheed Martin Outlook Amid Sustained Defense Demand RY Q1 2026 Earnings EPS Beats Estimates by 30 Amid Resilient Banking Operations PRH Q1 2026 Earnings Strong EPS Beat Amid Market Uncertainty Fortress Biotech Preferred Stock FBIOP Q4 2025 Earnings EPS Misses Estimates by Over 108 BWBBP Q1 2026 Earnings Preferred Stock EPS Slightly Misses Estimates Stock Declines Modestly Innovative Solutions and Support Inc ISSC Q1 2026 Earnings EPS Smashes Estimates by 477 as Shares Slip VMD Q1 2026 Earnings EPS Misses Estimates by 34 Amid Uncertain Revenue Outlook Neumora Therapeutics NMRA Slides 216 as Stock Tests Key Support Levels Marchex MCHX Edges Higher as Shares Test Key Resistance Near 176 Telus Corporation TU Edges Higher Amid Telecom Sector Stability UP Fintech TIGR Declines 137 as Price Approaches Key Support Zone Teads Holding Co TEAD Surges 126 as Stock Bounces from Key Support Bungie to End Major Content Updates for Destiny 2 Game Remains Playable After Final Patch IRIX Q1 2026 Earnings NarrowerthanExpected Loss Signals Operational Discipline Betterware de Mexico BWMX Surges 33 as Shares Approach Key Resistance Level TRNR Q1 2026 Earnings EPS Surprise Beats Estimates Despite No Revenue Alto Ingredients Inc ALTO Q1 2026 Earnings Profitability Surprise Drives Positive Sentiment OCSL Q1 2026 Earnings EPS Beats Estimates Stock Gains ADUS Q1 2026 Earnings EPS Beat Amidst Revenue Disclosure Gap Stock Edges Lower Biohaven Ltd BHVN Q1 2026 Earnings Wider Loss Than Expected as PreRevenue Biotech Advances Pipeline FSEA Q3 2024 Earnings Modest Profit Amid Narrowing Margins InMed Pharmaceuticals Q3 2025 Earnings Continued Losses as Stock Declines